Literature DB >> 24604604

Ocular surface evaluation in allogenic hematopoietic stem cell transplantation patients.

Murugesan Vanathi1, Seema Kashyap, Rehan Khan, Tulika Seth, Pravas Mishra, Manoranjan Mahapatra, Radhika Tandon.   

Abstract

PURPOSE: To evaluate ocular surface of chronic graft versus host disease (GVHD) patients in allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS: Cross-sectional study of allo-HSCT patients. Data recorded included Ocular Surface Disease Index (OSDI) score, fluorescein tear break-up time (FTBUT), Schirmer I test, ocular surface staining, dry eye severity, and conjunctival impression cytology (CIC).
RESULTS: Of 40 allo-HSCT patients (mean age 25.7 ± 11.03 years) studied, dry eye disease was noted in 30%. The OSDI was mild in 16.67%, moderate in 45.83%, and severe in 20.83% ocular GVHD (oGVHD) eyes; mild in 94.64%, moderate in 5.36% non-oGVHD eyes (p<0.001). The FTBUT was ≤5 seconds in 45.83%, >5 seconds in 54.17% of eyes with chronic oGVHD. Schirmer I test score was ≤5 mm in 58.33% of eyes with oGVHD. Conjunctival staining score was <3 in 25%, ≥3 in 75% of oGVHD eyes. Corneal staining score of <3 in 79.17%, ≥3 in 20.83% was seen in oGVHD eyes. Chronic oGVHD was seen in 24 eyes, with dry eye severity of level 3 in 17.5%, level 2 in 2.5%, level 1 in 10%. The CIC was abnormal in 75% with altered morphology seen in 22 eyes with oGVHD (91.7%) and 38 eyes without oGVHD (67.9%) (p = 0.024).
CONCLUSIONS: Significant ocular surface changes occur due to chronic oGVHD in allo-HSCT patients. The OSDI score, corneal involvement, and Schirmer I test are indicative of ocular morbidity in post allo-HSCT eyes. Conjunctival impression cytology abnormality is also seen in eyes without oGVHD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604604     DOI: 10.5301/ejo.5000451

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  6 in total

1.  Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice.

Authors:  G Giannaccare; F Bonifazi; M Sessa; E Dan; M Arpinati; M Fresina; G Bandini; M Cavo; P Versura; E C Campos
Journal:  Eye (Lond)       Date:  2017-05-19       Impact factor: 3.775

2.  Ocular manifestations of graft-versus-host disease: 10 years' experience.

Authors:  Xihui Lin; Harrison Dwight Cavanagh
Journal:  Clin Ophthalmol       Date:  2015-07-03

3.  Heavy Chain-Hyaluronan/Pentraxin 3 from Amniotic Membrane Suppresses Inflammation and Scarring in Murine Lacrimal Gland and Conjunctiva of Chronic Graft-versus-Host Disease.

Authors:  Yoko Ogawa; Hua He; Shin Mukai; Toshihiro Imada; Shigeru Nakamura; Chen-Wei Su; Megha Mahabole; Scheffer C G Tseng; Kazuo Tsubota
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

4.  Grading criteria for chronic ocular graft-versus-host disease: comparing the NIH eye score, Japanese dry eye score, and DEWS 2007 score.

Authors:  Yukako Tatematsu; Yoko Ogawa; Takayuki Abe; Mizuka Kamoi; Miki Uchino; Yumiko Saijo-Ban; Saori Yaguchi; Shin Mukai; Takehiko Mori; Shinichiro Okamoto; Kazuo Tsubota
Journal:  Sci Rep       Date:  2014-10-22       Impact factor: 4.379

5.  Comments on: Ocular surface characterization after allogeneic stem cell transplantation: A prospective study in a referral center.

Authors:  Sridevi Nair; Murugesan Vanathi
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

Review 6.  Update on ocular graft-versus-host disease.

Authors:  Sridevi Nair; Murugesan Vanathi; Ritika Mukhija; Radhika Tandon; Sandeep Jain; Yoko Ogawa
Journal:  Indian J Ophthalmol       Date:  2021-05       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.